<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002027</url>
  </required_header>
  <id_info>
    <org_study_id>038A</org_study_id>
    <secondary_id>JRD 64,433/1101</secondary_id>
    <nct_id>NCT00002027</nct_id>
  </id_info>
  <brief_title>Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)</brief_title>
  <official_title>Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of diclazuril capsules compared with placebo capsules as&#xD;
      treatment of cryptosporidial related diarrhea in AIDS patients. Treatment efficacy will be&#xD;
      based on the drug's clinical results and on its anti-protozoan effects. Safety will be&#xD;
      assessed by the occurrence of side effects as reported by patients at their visits and by&#xD;
      frequent monitoring of hematology, biochemistries, and urinalysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Cryptosporidiosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclazuril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Patients who require anti-diarrheal medication must have received only one&#xD;
             anti-diarrheal medication, loperamide, for at least 7 days prior to study entry. Dose&#xD;
             of loperamide cannot be increased during study.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
          -  Ganciclovir for cytomegalovirus (CMV) retinitis only but patient must be stable at&#xD;
             least 4 weeks prior to study entry.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Nystatin for oropharyngeal infections if not taken within 2 hours of diclazuril.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Diagnosis of AIDS that is confirmed HIV positive by Western blot or AIDS defined&#xD;
             diagnosis, or CDC defined AIDS. Stool specimens positive for cryptosporidium oocysts.&#xD;
&#xD;
          -  Given written informed consent after the purpose and nature of the study, as well the&#xD;
             possible drug-related adverse effects, have been explained.&#xD;
&#xD;
          -  Ability to return for all subsequent applicable visits on days 8, 15, 21, and, if&#xD;
             necessary, 28.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
          -  Loperamide.&#xD;
&#xD;
          -  Ganciclovir for cytomegalovirus (CMV) retinitis.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Diagnosis of cryptosporidiosis less than 4 weeks prior to study entry, unless patient&#xD;
             has been diagnosed with AIDS for more than 4 weeks.&#xD;
&#xD;
          -  Other treatable enteric pathogens including Clostridia must be treated and eradicated&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Inability to swallow capsules.&#xD;
&#xD;
          -  Uncontrolled vomiting.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Trimethoprim/sulfamethoxazole (Bactrim).&#xD;
&#xD;
          -  Ganciclovir for any other reason except cytomegalovirus (CMV) retinitis.&#xD;
&#xD;
          -  Other antibiotics.&#xD;
&#xD;
          -  Other anti-protozoal drugs.&#xD;
&#xD;
          -  Anti-fungal drugs other than nystatin.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Other investigational drugs.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Diagnosis of cryptosporidiosis less than 4 weeks prior to study entry, unless patient&#xD;
             has been diagnosed with AIDS for more than 4 weeks.&#xD;
&#xD;
          -  Inability to swallow capsules.&#xD;
&#xD;
          -  Uncontrolled vomiting.&#xD;
&#xD;
          -  Life expectancy of &lt; 28 days.&#xD;
&#xD;
          -  Can not be depended upon to follow the instructions of the investigator.&#xD;
&#xD;
          -  Participation in an investigational study within 15 days of study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 15 days of study entry:&#xD;
&#xD;
          -  Another investigational drug or device (except aerosolized pentamidine).&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 15 days of study entry:&#xD;
&#xD;
          -  Participation in an investigational study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr Douglas Dieterich</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Connolly G, Youle M, Gazzard B. Diclazuril in the treatment of cryptosporidial diarrhoea in AIDS. Int Conf AIDS. 1990 Jun 20-23;6(2):384 (abstract no 2122)</citation>
  </reference>
  <reference>
    <citation>Soave R, Dieterich D, Kotler D, Gassyuk E, Tierney AR, Liebes L, Legendre R. Oral diclazuril therapy for cryptosporidiosis. Int Conf AIDS. 1990 Jun 20-23;6(1):252 (abstract no ThB520)</citation>
  </reference>
  <verification_date>June 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Cryptosporidiosis</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>diclazuril</keyword>
  <keyword>Coccidiostats</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptosporidiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclazuril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

